netFormulary
 Report : Medicines with links to NICE 18/09/2019 02:08:58

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Abatacept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abemaciclib 08.01.05 Formulary NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA579]
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for metastatic hormone-relapsed prostate cancer before chemotherapy
Adalimumab 13.05.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 01.05.03 Restricted Use NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 10.01.03 Restricted Use NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab
Adalimumab 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 11.99.99.99 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Restricted Use NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept 11.08.02 Restricted Use NICE TA346: Macular oedema (diabetic)- aflibercept
Aflibercept 11.08.02 Restricted Use NICE TA305: Macular oedema (retinal vein occlusion)- aflibercept
Aflibercept 11.08.02 Restricted Use NICE TA409: Visual impairment caused by macular oedema after branch retinal vein occlusion- aflibercept.
Aflibercept 11.08.02 Restricted Use NICE TA 486: Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Formulary Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole tablets 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole tablets 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Asfotase alfa 09.08.01 Restricted Use NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia
Atezolizumab 08.02.03 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.02.03 Formulary NICE TA 492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.03 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.02.03 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Avelumab 10.01.03 Restricted Use NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 08.02.03 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.02.04 Formulary NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib ® 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Benralizumab 03.14 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Blinatumomab 08.02.03 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03 Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bosutinib 08.01.05 Formulary TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.02 Formulary NICE TA 511: Brodalumab for treating moderate to severe plaque psoriasis
Brodalumab 10.01.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (updated Aug 2016)
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes (June 2014)
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carfilzomib 08.01.05 Restricted Use NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Ciclosporin 1 mg/mL eye drops, emulsion 11.99.99.99 Formulary NICE TA369: Ciclosporin for treating dry eye disease (Dec 2015)
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.02.04 Formulary NICE TA 493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Colistimethate inhaler 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase clostridium histolyticum 10.03.01 Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA406:Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Cytarabine–daunorubicin liposomal 08.01.03 Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib with Trametinib 08.01.05 Formulary NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib with trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Non Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes (June 2013)
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes (November 2016)
Daratumumab 08.01.05 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Formulary NICE TA404:Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone 700mcg intravitreal implant 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for treatment of diabetic macular oedema
Dexamethasone 700mcg intravitreal implant 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate 13.05.03 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinutuximab 08.02.03 Formulary NICE TA 538: Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Restricted Use NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Docetaxel 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxorubicin Hydrochloride 08.01.02 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Doxylamine/pyridoxine 04.06 Non Formulary NICE Evidence Summary [ES20] Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy
Dronedarone tablets 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dupilumab 08.01.05 Formulary NICE TA 534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Formulary Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [TA578]
Edoxaban 02.08.02 Formulary TA354: Edoxaban for treating and preventing DVT and/or PE
Edoxaban 02.08.02 Formulary TA355: Edoxaban for preventing stroke and systemic embolism in people with atrial fibrillation
Eliglustat 09.08.01 Formulary NICE HST5: Eliglustat for treating type 1 Gaucher disease
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eluxadoline 01.05 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes (Mar 2015)
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)
Encorafenib with binimetinib 08.01.05 Formulary NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03 Formulary NICE TA153: Hepatitis B (chronic) - entecavir
Enzalutamide 08.03.04.02 Restricted Use NICE TA377: Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone tablets 02.02.03 Formulary NICE CG108: Chronic heart failure
Eribulin 08.01.05 Formulary TA423:Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA374: Lung cancer (non-small cell, locally advanced or metastatic)- erlotinib and gefitinib after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 13.05.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 06.01.02.03 Non Formulary NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
Exenatide prolonged release 06.01.02.03 Non Formulary NICE NG28:Type 2 diabetes in adults: management (Dec 2015)
Ezetimibe 02.12 Formulary NICE TA385: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Non Formulary NICE TA164: Hyperuricaemia - febuxostat
Febuxostat 10.01.04 Formulary NICE TA 164: Febuxostat for the management of hyperuricaemia in people with gout
Fingolimod 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE NG85: Pancreatic cancer in adults: diagnosis and management
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemtuzumab 08.02.03 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir–pibrentasvir 05.03.03.02 Formulary NICE TA 499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Glibenclamide 06.01.02.01 Formulary NICE NG 3: Diabetes in pregnancy: management from preconception to the postnatal period
Golimumab 10.01.03 Restricted Use NICE TA220: Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Goserelin 06.07.02 Formulary CKS guideline: Management of confirmed endometriosis- Secondary Care treatments
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 08.01.05 Formulary NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia (Oct 2015)
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA326: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib. NOT RECOMMENDED
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 01.05.03 Restricted Use NICE TA187: Crohn’s disease- infliximab (review) and adalimumab (review of TA40)
Infliximab 01.05.03 Restricted Use NICE TA329: Ulcerative Colitis (treatment)- Infliximab, adalimumab and golimumab
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Inotuzumab ozogamicin 08.02.03 Formulary NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Restricted Use NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan Hydrochloride 08.01.05 Non Formulary Negative NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Irinotecan Hydrochloride 08.01.05 Non Formulary Negative NICE TA 440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine tablets 02.06.03 Formulary NICE CG126: Management of Stable Angina
Ivabradine tablets 02.06.03 Formulary NICE TA267: Chronic heart failure - ivabradine
Ixazomib 08.01.05 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Formulary NICE TA 537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir- sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir-sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Restricted Use NICE TA171: Multiple myeloma - lenalidomide
Lenalidomide 08.02.04 Restricted Use NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Restricted Use NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenvatinib 08.01.05 Formulary NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Formulary NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Leuprorelin 06.07.02 Formulary CKS guideline: Management of confirmed endometriosis- Secondary Care treatments
Liraglutide 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
Lumacaftor-ivacaftor 03.15 Formulary NICE TA 398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lutetium (177Lu) oxodotreotide 08.03.04.03 Formulary Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation 03.07 Restricted Use TA266 Mannitol dry powder for inhalation for treating cystic fibrosis
Mepolizumab (Nucala®) 03.14 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methylprednisolone tablets 06.03.02 Formulary NICE CG186: Multiple Sclerosis in adults; management
Midostaurin 08.01.05 Formulary NICE TA523:Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Restricted Use NICE TA235: Mifamurtide for the treatment of osteosarcoma
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Nalmefene 04.10.01 Restricted Use NICE TA 325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: naloxegol
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone- bupropion 04.05.02 Non Formulary NICE TA 494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Restricted Use NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Niraparib 08.01.05 Formulary NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.03 Formulary NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.03 Formulary NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.03 Formulary NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.03 Formulary NICE TA 558:Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.03 Formulary NICE TA 490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.03 Formulary NICE TA 483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.03 Formulary NICE TA 484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.02.03 Formulary Nivolumab with ipilimumab for untreated advanced renal cell carcinoma [TA581]
Obeticholic acid 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA343: Untreated chronic lymphocytic leukaemia- obinutuzumab in combination with chlorambucil
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocriplasmin 11.08.02 Restricted Use NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA202: Chronic lymphocytic leukaemia refractory to fludaribine and alemtuzumab - ofatumumab is NOT recommended
Ofatumumab 08.02.03 Formulary NICE TA344: Untreated Chronic lymphocytic leukaemia- ofatumumab in combination with chlorambucil or bendamustine.
Ofatumumab 08.02.03 Formulary NICE TA470: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
Olaparib 08.01.05 Formulary NICE TA381: Olaparib for the maintenance treatment of ovarian, fallopian tube and peritoneal cancer
Omalizumab 13.05.03 Formulary NICE TA 339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.14 Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Omalizumab 03.14 Formulary NICE TA339: Previously treated chronic spontaneous urticaria- omalizumab
Omalizumab 03.04.02 Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Omalizumab 03.04.02 Formulary NICE TA339: Previously treated chronic spontaneous urticaria- omalizumab
Ombitasvir-paritaprevir-ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir-paritaprevir-ritonavir for treating chronic hepatitis C
Osimertinib 08.01.05 Formulary TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Restricted Use NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Paclitaxel 08.01.05 Restricted Use NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Padeliporfin 08.02 Non Formulary NICE TA546: Padeliporfin for untreated localised prostate cancer
Palbociclib 08.01.05 Formulary NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Panitumumab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Pegaspargase 08.01.05 Restricted Use NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia-
Peginterferon Alfa 08.02.04 Restricted Use NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (Oct 2015)
Pembrolizumab 08.01.05 Formulary NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (Nov 2015)
Pembrolizumab 08.01.05 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed - prior chemotherapy
Pemetrexed 08.01.03 Formulary NICE TA402: Lung cancer (non-squamous non-small-cell) after pemetrexed and cisplatin: Pemetrexed (maintenance)
Perampanel tablets 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 20 Restricted Use NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Non Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451:Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 16.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: quick reference guide on osteoporosis
Raltitrexed 08.01.03 Formulary NICE CG131:Colorectal cancer: diagnosis and management
Ranibizumab 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab 11.08.02 Restricted Use NICE TA155: Age-related Macular Degeneration- ranibizumab
Ranibizumab 11.08.02 Restricted Use NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 11.08.02 Restricted Use NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranolazine 02.06.03 Formulary NICE CG126: Management of Stable Angina
Regorafenib 08.01.05 Formulary NICE TA 555:Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Remote Control 01.01 Formulary Nice TA20
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Reslizumab 03.14 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.01.05 Formulary NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA 337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Formulary NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (Mar 2015)
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruloxitinib 08.01.05 Formulary NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Ruxolitinib 08.01.05 Formulary NICE TA289: Myelofibrosis (splenomegaly, symptoms) - ruxolitinib
Sacubitril valsartan 02.05.05 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (April 2016)
Sarilumab 08.02.04 Formulary NICE TA 485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Formulary TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary TA350: Secukinumab for treating moderate to severe plaque psoriasis
Sofosbuvir-velpatasvir-voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil tablets 10mg, 20mg ONLY 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Talimogene laherparepvec Restricted Item  08.01.05 Formulary NICE TA410: Unresectable metastatic melanoma- Talimogene laherparepvec
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Telbivudine 05.03.03.01 Formulary NICE TA154: Hepatitis B - telbivudine
Temozolomide 08.01.05 Formulary NICE TA23: Brain cancer - temozolomide
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temsirolimus 08.01.05 Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Restricted Use NICE TA303: Teriflunomide for relapsing remitting MS
Thalidomide capsules 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA236: Acute coronary syndromes - ticagrelor
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel 08.01.05 Formulary NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tisagenlecleucel 08.01.05 Formulary NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tivozanib 08.01.05 Formulary NICE TA512:Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Tocilizumab 10.01.03 Restricted Use NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab
Tocilizumab 10.01.03 Restricted Use NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Restricted Use NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.02.01 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.02.01 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 01.05.03 Formulary NICE TA 547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Formulary NICE TA 358:Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Restricted Use NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA389: Ovarian cancer (recurrent) - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer (advanced)- trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine-tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Triptorelin 06.07.02 Formulary CKS guideline: Management of confirmed endometriosis- Secondary Care treatments
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 10.01.03 Restricted Use NICE TA340: Active psoriatic arthritis- ustekinumab (rapid review of TA313)
Ustekinumab 01.05 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Vandetanib 08.01.05 Non Formulary NICE TA550: Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA342: Ulcerative colitis- vedolizumab
Vedolizumab 01.05.03 Restricted Use NICE TA352: Crohn’s disease after prior therapy- vedolizumab
Vemurafenib 08.01.05 Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vemurafenib 08.01.05 Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Venetoclax 08.01.05 Formulary NICE TA 487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Restricted Use NICE TA68: photodynamic therapy (PDT) to treat age-related macular degeneration (ARMD).
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary Negative NICE TA 489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary NICE TA367: Vortioxetine for treating major depressive episodes (Nov 2015)
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Birmingham, Sandwell, Solihull and environs APC Formulary